From the *Division of Gastroenterology, Hepatology, and Nutrition, The Children’s Hospital of Philadelphia, Philadelphia, PA.
Received June 6, 2022; accepted August 27, 2022.
B.D.C. has received Advanced Inflammatory Bowel Disease Fellowship training funding from Pfizer Inc, unrelated to this research. R.B. is a consultant for Pfizer, unrelated to this research. R.S. has received research funding from Janssen Research & Development LLC and Pfizer, unrelated to this research. L.A. has received research funding from Seres Therapeutics and speaker fees from Nestle Health Sciences, unrelated to this research. The remaining authors report no conflicts of interest.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal’s Web site (www.jpgn.org).
Sources of Funding: This work was supported in part by Pfizer Inc [grant number 66353149 to BDC]. This source of funding was independent of the submitted research and played no role in study design, collection, analysis, interpretation of the data, or in the writing of the report.
Address correspondence and reprint requests to Brad D. Constant, MD, MSCS, Children’s Hospital of Philadelphia, 3401 Civic Center Blvd, Philadelphia, PA 19104 (e-mail: [email protected]).